Get the Stockscreener App
23.02
5.23%
-1.27
After Hours:
23.00
-0.02
-0.09%
Quidelortho Corporation stock is traded at $23.02, with a volume of 1.79M.
It is down -5.23% in the last 24 hours and down -20.12% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$24.29
Open:
$23.99
24h Volume:
1.79M
Relative Volume:
1.12
Market Cap:
$1.56B
Revenue:
$2.76B
Net Income/Loss:
$-358.70M
P/E Ratio:
-4.6318
EPS:
-4.97
Net Cash Flow:
$-35.90M
1W Performance:
-12.57%
1M Performance:
-20.12%
6M Performance:
-47.03%
1Y Performance:
-41.41%
1-Day Range:
$22.89
$24.21
1-Week Range:
$22.89
$27.42
52-Week Range:
$22.89
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
23.02 | 1.64B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
What is the risk reward ratio of investing in QuidelOrtho Corporation stockFinancial News Updates Backed By Experts - jammulinksnews.com
Earnings Preview: QuidelOrtho to Report Financial Results Post-market on August 05 - 富途牛牛
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ - The Malaysian Reserve
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ | QDEL Stock News - GuruFocus
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know - Yahoo Finance
Stocks making big moves yesterday: Tesla, Super Micro, Nike, QuidelOrtho, and Limbach - TradingView
How QuidelOrtho Corporation stock reacts to Fed policy changesSecure Return Focused Investment Plan Released - beatles.ru
QuidelOrtho Stock Faces Continued Downturn as Investors Await EarningsNews and Statistics - IndexBox
Why QuidelOrtho (QDEL) Shares Are Sliding Today - Yahoo Finance
What are analysts’ price targets for QuidelOrtho Corporation in the next 12 monthsDiscover investment plans that deliver results - jammulinksnews.com
How many analysts rate QuidelOrtho Corporation as a “Buy”High-impact stock picks - jammulinksnews.com
What catalysts could drive QuidelOrtho Corporation stock higher in 2025Invest smarter with actionable market insights - jammulinksnews.com
Is QuidelOrtho Corporation a good long term investmentTriple-digit return opportunities - PrintWeekIndia
What drives QuidelOrtho Corporation stock priceRapidly expanding wealth - PrintWeekIndia
What analysts say about QuidelOrtho Corporation stockGame-changing returns - Autocar Professional
Can QuidelOrtho Corporation stock recover from recent declineExplosive returns - jammulinksnews.com
Is QuidelOrtho Corporation stock overhyped or has real potentialTremendous financial leverage - jammulinksnews.com
Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast - Nasdaq
QuidelOrtho Corporation Stock Analysis and ForecastFree Stock Market Forecast Reports - Autocar Professional
Real Labs, Actual Decisions With Actionable Six Sigma Metrics - Nasdaq
QuidelOrtho to Report Second Quarter 2025 Financial Results | QDEL Stock News - GuruFocus
QuidelOrtho to Report Second Quarter 2025 Financial Results - Stock Titan
QuidelOrtho and BÜHLMANN launch FCAL turbo and FPELA turbo assays on VITROS Systems - SelectScience
RBC Capital Maintains a Buy Rating on QuidelOrtho Corporation (QDEL), Sets a $60 PT - MSN
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):